Cell Line News and Research

RSS

IONTAS announces a new collaboration to identify novel immunotherapy targets

Antibody discovery agreement will support the development of new therapeutics for acute and chronic inflammatory syndromes.

From FairJourney Biologics 7 May 2020

Study discovers inhibition of SARS-CoV-2 entry priming protein by approved drug

The COVID-19 pandemic caused by the severe acute respiratory syndrome -coronavirus 2 (SARS-CoV-2) has spread to most of the world, causing millions of cases and hundreds of thousands of deaths. A new study published on the preprint server bioRxiv* shows that a protease inhibitor drug already approved by the Food and Drug Administration (FDA) could inhibit viral entry.

6 May 2020

OXGENE™ reports third consecutive year of 100% year on year revenue growth

OXGENE™ has more than doubled its annual revenue in the financial year just closed, in the third consecutive year of 100% year on year revenue growth.

From OXGENE 6 May 2020

Study finds two FDA-approved drugs are promising against COVID-19

Korean researchers have screened 48 FDA-approved drugs against SARS-CoV-2, and found that two, that are already FDA-approved for other illnesses, seem promising.

5 May 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

Kurome secures license to develop novel therapies for chemo-resistant cancer

Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.

29 Apr 2020

Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy

Horizon Discovery Group plc, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for cancer diagnostic assays.

From Revvity 29 Apr 2020

Recombinant protein produces neutralizing COVID-19 antibodies in primate model

A new study reports the induction of high levels of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing the current pandemic of COVID-19. This promising finding was reported on the preprint server bioRxiv on April 2020.

26 Apr 2020

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

FDB announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies.

From OXGENE 23 Apr 2020

Researchers demonstrate how TB bacteria import vitamin B12 molecules to grow

Researchers from Russia, the Netherlands, Sweden, and the U.S. have revealed the structure of the protein responsible for vitamin B12 import into the cells of the bacterium that causes tuberculosis. The research findings were published in Nature.

23 Apr 2020

Accelerating Antibody Discovery with Next-Generation Single-Cell Analysis

Accelerating antibody discovery using picodroplet technology for single cell analysis to condense discovery times down to 1-2 days.

From Fluidic Sciences and Sphere Bio 22 Apr 2020

Researchers uncover how cancer cells don their invisibility cloaks

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results. But exactly how cancer cells turn on this protein was not completely understood.

22 Apr 2020

Sphere Fluidics receives Queen’s Award for Enterprise

Sphere Fluidics, has be honored with a Queen’s Award for Enterprise for Innovation.

From Fluidic Sciences and Sphere Bio 21 Apr 2020

Scientists discover anti-cancer compound in the humble willow

More than a century after giving the world aspirin, another potential drug has been found in the stem and leaves of willows – this time with anti-cancer properties.

17 Apr 2020

Gold-containing drug auranofin kills 95% of SARS-CoV-2 virus in 48 hours in lab conditions

A drug called auranofin, approved for the treatment of rheumatoid arthritis, effectively inhibits severe acute respiratory syndrome coronavirus (SARS-CoV-2) in laboratory conditions, as described in a new study by Georgia State University researchers.

16 Apr 2020

Horizon Discovery offers rapid access to CHOSOURCE platform for development of COVID-19 therapies

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.

16 Apr 2020

Horizon Discovery expands cell-based CRISPR screening services

Horizon Discovery Group plc, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells.

From Revvity 6 Apr 2020

Scientists examine the molecular causes of rare hereditary disease

Scientists in EMBL Barcelona’s Ebisuya group, with collaborators from RIKEN, Kyoto University, and Meijo Hospital in Nagoya, Japan, have studied oscillating patterns of gene expression, coordinated across time and space within a tissue grown in vitro, to explore the molecular causes of a rare human hereditary disease known as spondylocostal dysostosis.

5 Apr 2020

Investigating Human Disease with Mass Spectrometry-based Proteomics

Dr. Andrew Webb describes how his lab uses mass spectrometry-based techniques to understand the role of post-translational modifications in human disease.

From Bruker Daltonics 3 Apr 2020

Horizon Discovery and Pharmahungary report positive early-stage results for novel micro-RNA therapeutic for ischemic heart diseases

Horizon Discovery Group plc and Pharmahungary Group announced positive early-stage results for a novel micro-RNA therapeutic for ischemic heart diseases.

31 Mar 2020